Early Life
Born on January 28, 1965, Zhao Tao is a Singaporean citizen with a strong educational background, including an MBA from Fordham University. While details of his early life are not widely available, his later career choices indicate a focus on business and finance.
Rise to Success
Zhao Tao's rise to prominence is largely attributed to his involvement in the pharmaceutical sector. He is the chairman of Shandong Buchang Pharmaceuticals, a company that specializes in traditional Chinese medicine. He started the company with his father Zhao Buchang in 1993. He has been a key player in the success and growth of Sino Biopharmaceutical, a major player in the Chinese pharmaceutical market.
Key Business Strategies
Key business strategies include a focus on innovative products and expansion. Sino Biopharmaceutical is investing heavily in research and development, which is about 17.6% of its revenue. They are also strategically expanding their product portfolio through acquisitions, such as LaNova Medicines. Sino Biopharmaceutical focuses on products for the treatment of hepatitis, cardio-cerebral diseases, cancer, orthopedic conditions, infectious diseases, and respiratory and digestive diseases.
Philanthropy
While specific philanthropy details are unavailable, Zhao Tao is involved with the general trends of the Pharmaceutical industry. Sino Biopharmaceutical’s actions are geared toward a commitment to healthcare solutions.